Loading, Please Wait...
CHARLOTTE, N.C., May 23, 2019 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY), the Dental Solutions Company, today announced that the Board of Directors approved the relocation of the Company’s principal executive offices from York, Pennsylvania to its offices at Ballantyne Corporate Place, Charlotte, North Carolina. The move builds on Dentsply Sirona’s reorganization plan to centralize its sales and service infrastructure in Charlotte, to further simplify the organization and to enhance the Company’s clinical education capabilities and functionality at the Dentsply Sirona Charlotte Academy.
Nicholas W. Alexos, the Company’s Executive Vice President and Chief Financial Officer, will be leaving the Company in connection with the relocation of its headquarters. To ensure a smooth leadership transition, Mr. Alexos will continue to serve as Chief Financial Officer and will remain an active member of the company’s leadership team as the Company conducts a formal search for his replacement and until his successor is appointed.
"On behalf of the entire management team, I would like to thank Nick for his partnership and contribution to Dentsply Sirona” said Don Casey, Chief Executive Officer. “Nick was essential in framing the restructuring plan, helping to develop our growth strategy and executing on our successful portfolio shaping initiatives.”
About Dentsply Sirona
Dentsply Sirona is the world’s largest manufacturer of professional dental products and technologies, with a 132-year history of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world class brands. As The Dental Solutions Company, Dentsply Sirona’s products provide innovative, high-quality and effective solutions to advance patient care and deliver better, safer and faster dentistry. The Company’s shares of common stock are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.
John Sweeney, CFA, IRC
Vice President, Investor Relations
Forward-Looking Statements and Associated Risks
Information the Company has included or incorporated by reference in this Form 8-K, and information which may be contained in other filings with the U. S. Securities and Exchange Commission (the “SEC”) as well as press releases or other public statements, contains or may contain forward-looking statements. These forward-looking statements include, among other things, statements about the completion of the year-end financial statement audit and expected financial results referred to herein, and/or statements about the Company’s plans, objectives, expectations (financial or otherwise) or intentions, including the Company's 2019 guidance.
The Company’s forward-looking statements involve risks and uncertainties. Actual results may differ significantly from those projected or suggested in any forward-looking statements. The Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events. Any number of factors could cause the Company’s actual results to differ materially from those contemplated by any forward-looking statements, including, but not limited to, the risks associated with the following:
You should carefully consider these and other relevant factors, including those risk factors in Part I, Item 1A, “Risk Factors” in the Company's most recent Form 10-K and any other information included or incorporated by reference in this Report, and information which may be contained in the Company’s other filings with the SEC, when reviewing any forward-looking statement. Investors should understand it is impossible to predict or identify all such factors or risks. As such, you should not consider either foregoing lists, or the risks identified in the Company’s SEC filings, to be a complete discussion of all potential risks or uncertainties associated with an investment in the Company.